Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

News Press Release Media Report

Year:

Select

Press Release

13 March 2026

Alphamab Oncology Announces IND Application for Innovative EGFR/HER3 Dual Payload Bispecific ADC JSKN021 was Officially Accepted by CDE JSKN021 showed stronger tumor inhibition efficacy than mono payload ADCs in multiple CDX models
11 March 2026

Alphamab Oncology Appoints Dr. Hongwei Wang as Chief Technology Officer Dr. Wang's joining will accelerate the global development and commercialization of the company's innovative product pipeline
14 February 2026

Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2-targeting ADC JSKN003 is expected to provide patients with a new therapeutic option
04 February 2026

World Cancer Day | People-Centered Innovation Lighting the Way for Hope People-Centered, United Against Cancer
27 Janurary 2026

Alphamab Oncology Announces the Results of a Phase III Clinical Study of Anbenitamab (KN026) were Published in Annals of Oncology the positive results robustly demonstrate that anbenitamab combined with chemotherapy has the potential to become a new standard of care for patients with HER2-positive gastric cancer who have failed ...
29 December 2025

Alphamab Oncology Announces IND Application for a Phase II Clinical Study of HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 as First-line Treatment of Advanced Cervical Cancer was Officially Accepted by CDE JSKN033 in combination with platinum-based chemotherapy with or without bevacizumab as first-line treatment of advanced cervical cancer
23 December 2025

Envafolimab Was Granted Another Orphan Drug Designation by the U.S. FDA for the Treatment of GC/GEJ This marks the third ODD awarded to Envafolimab, following previous designations for advanced biliary tract cancer and soft tissue sarcoma
22 December 2025

Alphamab Oncology Announces Bispecific ADC JSKN016 in Combination with InventisBio's D-0502 Approved for Clinical Trial in Breast Cancer Treatment for the treatment of locally advanced or metastatic HR-positive, HER2-negative (HR+/HER2-) breast cancer
20 December 2025

Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Breakthrough Therapy Designation by the FDA for the Treatment of PROC The grant of this BTD further demonstrates the international regulatory community’s recognition of JSKN003’s clinical potential and its importance as a novel therapeutic candidate
18 December 2025

Alphamab Oncology Announces IND Application for Innovative PD-L1/VEGFR2 Bispecific ADC JSKN027 was Officially Accepted by CDE The Company plans to initiate a clinical study of JSKN027 for the treatment of advanced malignant solid tumors